Daewoong Pharmaceutical announced on September 15 that it will broadcast a web symposium on September 16 through its medical information platform, Dr.Ville, focusing on the theme of 'Paradigm Shift in Blood Sugar Management.'
The event is designed to share the latest clinical practices utilizing Continuous Glucose Monitoring (CGM) with healthcare professionals in South Korea. CGM measures blood sugar changes in real-time and continuously through a sensor attached to the skin, allowing for a comprehensive view of blood sugar fluctuations over a day, unlike traditional fingertip blood tests.
Professor Choi Sung-hee from Bundang Seoul National University Hospital will serve as the moderator, while Professor Min Se-hee from Asan Medical Center and Professor Motozugu Nagao from Tokyo Women's Medical University will present. Daewoong Pharmaceutical has invited Professor Nagao to share Japan's latest clinical experiences.
Professor Nagao will deliver a lecture titled 'From Monitoring to Management: A New Diabetes Management Model with CGM.' In Japan, the insurance coverage for CGM has expanded, making it actively used in routine care for both Type 1 and insulin-treated Type 2 diabetes patients.
Professor Min Se-hee will explain the guidelines for using integrated continuous glucose monitors (iCGM) recommended by the U.S. Food and Drug Administration (FDA). He will cover the indications, measurement accuracy across blood sugar ranges, and considerations for using CGM data in clinical settings.
Moderator Choi Sung-hee will lead discussions centered on the latest clinical evidence related to CGM and how to connect CGM data with patients' lifestyles and self-management, sharing various clinical perspectives from healthcare professionals in Korea and Japan.
Park Hyung-cheol, head of Daewoong Pharmaceutical's ETC Marketing Division, stated, "Recent diabetes management has expanded beyond simply checking blood sugar levels to helping patients understand their blood sugar data and enhance their self-management capabilities. We hope that useful insights can be widely shared amid the changing paradigm of blood sugar management."
Meanwhile, Daewoong Pharmaceutical has recently been selected as a partner in the 'Blood Sugar Catch 9988' initiative, a citizen blood sugar management support project promoted by the Seoul Metropolitan Government. This project targets 1,000 Seoul residents identified as pre-diabetic with fasting blood sugar levels between 100-125 mg/dL through health center metabolic syndrome screenings.
The event is designed to share the latest clinical practices utilizing Continuous Glucose Monitoring (CGM) with healthcare professionals in South Korea. CGM measures blood sugar changes in real-time and continuously through a sensor attached to the skin, allowing for a comprehensive view of blood sugar fluctuations over a day, unlike traditional fingertip blood tests.
Professor Choi Sung-hee from Bundang Seoul National University Hospital will serve as the moderator, while Professor Min Se-hee from Asan Medical Center and Professor Motozugu Nagao from Tokyo Women's Medical University will present. Daewoong Pharmaceutical has invited Professor Nagao to share Japan's latest clinical experiences.
Professor Nagao will deliver a lecture titled 'From Monitoring to Management: A New Diabetes Management Model with CGM.' In Japan, the insurance coverage for CGM has expanded, making it actively used in routine care for both Type 1 and insulin-treated Type 2 diabetes patients.
Professor Min Se-hee will explain the guidelines for using integrated continuous glucose monitors (iCGM) recommended by the U.S. Food and Drug Administration (FDA). He will cover the indications, measurement accuracy across blood sugar ranges, and considerations for using CGM data in clinical settings.
Moderator Choi Sung-hee will lead discussions centered on the latest clinical evidence related to CGM and how to connect CGM data with patients' lifestyles and self-management, sharing various clinical perspectives from healthcare professionals in Korea and Japan.
Park Hyung-cheol, head of Daewoong Pharmaceutical's ETC Marketing Division, stated, "Recent diabetes management has expanded beyond simply checking blood sugar levels to helping patients understand their blood sugar data and enhance their self-management capabilities. We hope that useful insights can be widely shared amid the changing paradigm of blood sugar management."
Meanwhile, Daewoong Pharmaceutical has recently been selected as a partner in the 'Blood Sugar Catch 9988' initiative, a citizen blood sugar management support project promoted by the Seoul Metropolitan Government. This project targets 1,000 Seoul residents identified as pre-diabetic with fasting blood sugar levels between 100-125 mg/dL through health center metabolic syndrome screenings.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.